The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Is CLL chemoimmunotherapy finished?
Robin Foà
• 1 Dec 2018
Robin Foà, MD, of Sapienza University of Rome, Rome, Italy, gives us his take on the key chronic lymphocytic leukemia (CLL) highlights from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Prof. Foà highlights novel agents changing the treatment landscape.
